Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Proagio by ProDa BioTech for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Proagio is under clinical development by ProDa BioTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Data Insights
Proagio by ProDa BioTech for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Proagio is under clinical development by ProDa BioTech and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...